Its therapeutic applications include cardiovascular and neurological diseases. Requirement 1: in accordance with general formula (1): m1-l-m2 (1), the complex of descendant fund recipients, where M 1 and M 2 are the same or different, each representing a single m unit and l unit, representing a combination of M 1 and M 2 in a mixed way. The M-type monotone responds to the general formula (2), where * denotes the connection point between the M-type monotone device and the L-type Union； R1 represents a group - nhcop h, which is substituted by oxygen atom,Since the oxygen atom is the connection point between the monomer device and the L Union, you can see this group - nhcopho *,Or an arilo group, especially a phenyl or isomerized group, is replaced by a group selected from different oxygen atoms, so that the oxygen atom is the connection point between the monomer and the L adhesive, or an Amida CONH * group, so that the nitrogen atom is the connection point between the monomer and the L adhesive. l. R2 represents a tar group； R3 represents a hydrogen atom, or a linear, cyclic or partially cyclic tar group； r830808 represents a hydrogen atom or a tar group - tar group - synergy 83099, represents a hydrogen atom or a tar group；In the form of a base or salt of an acid or base.Su aplicación terapéutica comprende enfermedades cardiovasculares y neuronales. Reivindicación 1: Compuestos agonistas de los receptores de los FGF que responden a la fórmula general (1): M¹-L-M² (1) en la que M¹ y M² idénticos o diferentes representan cada uno independientemente entre sí una unidad monómera M y L representa un grupo de unión que une M¹ y M² de forma covalente, caracterizados por que dicha unidad monómera M responde a la fórmula general (2) en la que, * indica que el sitio de unión entre la unidad monómera M y el ligante L； R¹ representa un grupo -NHCOPh, estando dicho fenilo sustituido con un átomo de oxígeno, tal que el átomo de oxígeno es el sitio de unión entre la unidad monóme
